Targeting TGF–beta for treatment of disease

Nature Medicine

Volumn 1, Issue 10, 1995, Pages 1000-1001

  Border, Wayne A ^a   Noble, Nancy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; RECEPTOR BLOCKING AGENT; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNITY; DRUG THERAPY; FIBROSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION; WOUND HEALING;

ANIMAL; ARTERIOSCLEROSIS; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0028825322     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1095-1000     Document Type: Article

References (16)

1. Grainger, D J., Witchell, C.M. & Metcalfe, J.C. Tamoxifen elevates transforming growth factor-β and suppresses diet-induced formation of lipid lesions in mouse aorta. Nature Med. 1, 1067-1073 (1995).
2. Sporn, M.B. & Roberts, A.B. A major advance in the use of growth factors to enhance wound healing. J. Clin. Invest, 92, 2565-2566 (1993).
3. Beck, L.S. et al. One systemic administration of transforming growth factor-β1 reverses age* or glucocorticoid-impaired wound healing. J. clin. Invest. 92, 2841-2849 (1993).
4. Wahl, S.M. Transforming growth factor β: The good, the bad, and the ugly. J, exp. Med. 180, 1587-1590(1994).
5. Border, W.A. & Noble, N.A. Transforming growth factor β in tissue fibrosis. New Engl. J. Med. 331, 1286-1292 (1994).
6. Kadin, M.E. et al. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc. natn. Acad. Sci. U.SA. 92, 6002-6006 (1994).
7. Markowitz, S. et al. Inactivation of the type IITGF-β receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338 (1995).
8. Kofima, S., Harpel, P.C. & Rifkin, D.B. Lipoprotein (a) inhibits the generation of transforming growth factor β; An endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113, 1439-1445(1991).
9. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809 (1993).
10. Grainger, D J. et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med. I, 74-79 (1995).
11. Dickson, K., Philip, A., Warshawsky, H., O’Connor-McCourt, M. & Bergeron, J.J.M. Specific binding of endocrine transforming growth factor-β 1 to vascular endothelium. J. clin. Invest. 95, 2539-2554 (1995).
12. Nikol, S. et al. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J. clin. Invest. 90, 1582-1592 (1992).
13. Wolf, Y.G., Rasmussen, L.M. & Ruoslahti, E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J. clin. Invest. 93, 1172-1178 (1994).
14. Nabel, E.G. et al. Direct transfer of transforming growth factor β1 gene into arteries stimulates fi-brocellular hyperplasia. Proc. natn. Acad. Sci. U.S.A. 90, 10759-10763 (1993).
15. Zugmaler, G. et al. Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res. 51, 3590-3594(1991).
16. Anscher, M.S. et al. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New Engl. J. Med. 328, 1592-1598(1993).